Osimertinib was also approved in 2018 as first-line therapy for advanced EGFR-mutated NSCLC, regardless of T790M mutation status.6 However, despite the robust clinical activity exerted by osimertinib, patients inevitably develop secondary resistance to this treatment, which poses a significant challenge due to the paucity of post-osimertinib pharmacological options available to date. Here, EGFR is linked to non-small cell lung carcinoma.